Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain
- PMID: 3037066
Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain
Abstract
Previous autoradiographic studies which have localized alpha-2 adrenoceptors within brain have used tritiated derivatives of clonidine and other alpha-2 adrenergic agonists. In the present study we have compared the autoradiographic distributions of binding sites labeled by two reportedly selective alpha-2 adrenoceptor antagonists, [3H]rauwolscine and [3H]idazoxan, in rat brain. The distribution of high affinity [3H]idazoxan binding sites differed markedly from that of high affinity [3H]rauwolscine sites throughout the neuraxis. The distribution of [3H]idazoxan binding sites paralleled closely that of [3H]clonidine sites, and corresponded to areas of noradrenergic innervation. Densest [3H]idazoxan labeling appeared over anterior olfactory nuclei, fundus striatum, septum, thalamus, hypothalamus, amygdala, entorhinal cortex, central gray, inferior colliculus, dorsal parabrachial nucleus, locus ceruleus and nucleus of the solitary tract. In contrast, much lower levels of [3H]rauwolscine labeling appeared over several areas which receive primarily dopaminergic innervation, and thus corresponded closely to [3H]spiroperidol binding distributions. Densest [3H]rauwolscine labeling appeared over nucleus caudate-putamen, nucleus accumbens, olfactory tubercle, Islands of Calleja, hippocampus, parasubiculum, basolateral amygdaloid nucleus and substantia nigra. In areas labeled by [3H]rauwolscine, computerized densitometric analysis of autoradiographic saturation curves revealed that the maximum binding values for [3H]idazoxan high affinity binding sites were consistently greater than those for high affinity [3H]rauwolscine sites. The pharmacological characterization of these two binding sites in the accompanying paper supports the present anatomical evidence that [3H]idazoxan labels a heterogenous population of alpha-2 adrenoceptor sites, one population of which is selectively labeled by [3H]rauwolscine.
Similar articles
-
Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain.J Pharmacol Exp Ther. 1987 Jun;241(3):1092-8. J Pharmacol Exp Ther. 1987. PMID: 2885406
-
[3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site.Mol Pharmacol. 1989 Mar;35(3):324-30. Mol Pharmacol. 1989. PMID: 2564631
-
Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines.J Pharmacol Exp Ther. 1995 Jun;273(3):1287-94. J Pharmacol Exp Ther. 1995. PMID: 7791100
-
Idazoxan: a novel pharmacological tool for the study of alpha 2-adrenoceptors.J Pharmacol. 1986 Apr-Jun;17(2):113-8. J Pharmacol. 1986. PMID: 2875218 Review.
-
Autoradiography of adrenoceptors in rat and human brain: alpha-adrenoceptor and idazoxan binding sites.Prog Brain Res. 1991;88:271-91. doi: 10.1016/s0079-6123(08)63816-9. Prog Brain Res. 1991. PMID: 1667546 Review.
Cited by
-
Distribution of alpha 2-adrenergic binding sites in the parabrachial complex of the rat.Anat Embryol (Berl). 1995 Dec;192(6):507-16. doi: 10.1007/BF00187181. Anat Embryol (Berl). 1995. PMID: 8751108
-
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.J Mol Neurosci. 2012 Jan;46(1):145-52. doi: 10.1007/s12031-011-9539-x. Epub 2011 May 12. J Mol Neurosci. 2012. PMID: 21562737
-
Quantification of [(11)C]yohimbine binding to α2 adrenoceptors in rat brain in vivo.J Cereb Blood Flow Metab. 2015 Mar;35(3):501-11. doi: 10.1038/jcbfm.2014.225. Epub 2015 Jan 7. J Cereb Blood Flow Metab. 2015. PMID: 25564241 Free PMC article.
-
Modulation of central noradrenergic function by RS-15385-197.Br J Pharmacol. 1993 Feb;108(2):526-33. doi: 10.1111/j.1476-5381.1993.tb12835.x. Br J Pharmacol. 1993. PMID: 8095421 Free PMC article.
-
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats.J Neurosci. 2007 Sep 5;27(36):9595-606. doi: 10.1523/JNEUROSCI.2583-07.2007. J Neurosci. 2007. PMID: 17804620 Free PMC article.